trending Market Intelligence /marketintelligence/en/news-insights/trending/fZlMLnpdwx3T6SyBC8fQ1A2 content esgSubNav
In This List

NICE approves use of Merck's Keytruda under cancer fund

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


NICE approves use of Merck's Keytruda under cancer fund

The U.K.'s National Institute for Health and Care Excellence cleared the use of Merck & Co. Inc.'s cancer drug Keytruda in previously untreated lung cancer patients under funding arrangements within the Cancer Drugs Fund, Reuters reported.

The agency did not recommend the routine use of the drug for newly diagnosed patients due to its high cost and uncertainties about overall survival benefits.